Giorgio Maria Verdecchia

Giorgio Maria Verdecchia

Auto-generated profile, based on publicly available information

Giorgio Maria Verdecchia

Unit of Surgery and Advanced Oncologic Therapies, Morgagni-Pierantoni Hospital, Forlì, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ABAlberto Bongiovanni
Alberto Bongiovanni
NRNada Riva
Nada Riva
MRMarianna Ricci
Marianna Ricci
LMLaura Mercatali
Laura Mercatali
CLChiara Liverani
Chiara Liverani
Toni IbrahimToni Ibrahim
Toni Ibrahim
Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. The prognosis for this tumor is poor, with survival rates among the lowest of all soft tissue sarcomas. Surgery is the best approach for localized disease. The principal role of chemotherapy is prevalently in the treatment of metastatic disease. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that differs from that of traditional alkylating agents, has been approved in Europe for the treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, We report the case of a 53-year-old woman with metastatic well differentiated uterine leiomyosarcoma refractory to multiple treatments who underwent 22 cycles of trabectedin over 30 months, obtaining a partial response according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, with good tolerability, and maintaining the response for 10 months after trebectedin withdrawal. This very prolonged response, which persisted after drug discontinuation, suggests that trabectedin exerts an oncostatic effect rather than the cytotoxic one produced by other chemotherapeutic agents. Our experience also raises the question of the best way to evaluate trabectedin efficacy.

16 May 2007
Verified
Journal Article
Closed access
GMGianni Mura
Gianni Mura
MFMassimo Framarini
Massimo Framarini
AVAlessio Vagliasindi
Alessio Vagliasindi
DCDavide Cavaliere
Davide Cavaliere
FTfrancesca tauceri
francesca tauceri
GVGiorgio Maria Verdecchia
Giorgio Maria Verdecchia